Table 1 Blood pressure analyses
Isoflurane (n = 23) | Xenon (n = 23) | P-value | |
|---|---|---|---|
Blood pressure, median (IQR), mm Hg | |||
Systolic blood pressure | 105.7 [100.9–113.0] | 114.2 [104.4–131.3] | 0.020* |
Diastolic blood pressure | 64.0 [56.9–68.5] | 75.1 [63.9–83.2] | 0.011* |
Duration of systolic blood pressure deviation, median (IQR), minutes | |||
Decrease > 40% from baseline | 5.0 [0–35.0] | 2.5 [0–12.5] | 0.510 |
Decrease > 20% from baseline | 110.0 [47.5–162.5] | 60.0 [12.5–120.0] | 0.018* |
Increase > 20% from baseline | 0 [0–2.5] | 0 [0–15.0] | 0.049* |
Proportion of the study treatment duration represented by the systolic blood pressure deviation duration, median (IQR), % | |||
Decrease > 40% from baseline | 2 [0–18.0] | 0 [0–7.7] | 0.549 |
Decrease > 20% from baseline | 76.9 [26.5–90.9] | 33.3 [6.7–77.5] | 0.170 |
Increase > 20% from baseline | 0 [0–0.9] | 0 [0–6.6] | 0.036* |
MAP, median (IQR), mmHg | 77.2 [72.2–85.1] | 84.2 [75.8–100.9] | 0.029* |
Duration of MAP decrease, median (IQR), minutes | |||
MAP < 65 mmHg | 25.0 [10.0–47.5] | 0 [0–10.0] | < 0.002** |
MAP < 60 mmHg | 5.0 [0–17.5] | 0 [0–5.0] | 0.041* |
Proportion of the study treatment duration represented by the MAP decrease, median (IQR), % | |||
MAP < 65 mmHg | 16.7 [4.2–22.8] | 0 [0–5.8] | < 0.004** |
MAP < 60 mmHg | 3.9 [0–9.5] | 0 [0–3.1] | 0.048* |